

Ministerial (Bio-Pharmaceutical) Industry Strategy Group
9.30am – 11.30am Wednesday 9th July 2014
Board Room, Richmond House, Whitehall

**Agenda: Next steps in the relationship between UK Government and the
Pharmaceutical Industry**

1. **Welcome** from Pascal Soriot, CEO, AstraZeneca, Chair
2. **Agreement of minutes from November meeting** MISG 14(02)
3. **Manufacturing** [30 mins] - introduced by Ian McCubbin, Chair of the Medicines Manufacturing Industry Partnership (MMIP) - discussion on establishment of MMIP, its vision, achievements and opportunities for investment. Four recommendations seeking agreement:
 - a) Human Resource commitments (industry and Government)
 - b) Embedding Medicines Manufacturing in funders strategies
 - c) Establishing a centre for Digital Design of Medicines and a National Formulation Centre
 - d) Review the fiscal environment for medicines manufacture.

Paper produced by MMIP MISG 14(03)
4. **R&D environment** [30 mins] – presented by Dr Mene Pangalos on behalf of the industry- government working group of companies, trade associations and government. The accompanying paper recommends that MISG:
 - a) endorse the level of the ambition statement in the paper
 - b) endorse the emergent themes
 - c) endorse the requirement for concerted partnership across MISG members to lead a step change in the UK research ecosystem
 - d) endorse the proposed next steps.

Paper produced by government industry working group MISG 14(04)
5. **PPRS Implementation and Medicines Optimisation** [40 mins] - developments since the last MISG meeting and a discussion on medicines access in the context of the opportunity presented by Medicines Optimisation.

Paper jointly produced by NHSE and ABPI MISG 14(05)
6. **A.O.B** – papers to note for information
 - UKTI Communications MISG 14(06)
 - UK Health Life Sciences Competitiveness Indicators MISG 14(07)
 - Skills – Science Industry Partnership MISG 14(08)

7. **Close**